7.63k followers • 30 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks that have set 52-week highs within the last week. This list is generated daily, ranked by market cap and limited to the top 30 stocks that meet the criteria.
Applied Materials, Inc.
Advanced Micro Devices, Inc.
Rockwell Automation Inc.
Marvell Technology Group Ltd.
Skyworks Solutions, Inc.
WellCare Health Plans, Inc.
Seagate Technology plc
Nomura Holdings, Inc.
The Liberty SiriusXM Group
The Liberty SiriusXM Group
Lamb Weston Holdings, Inc.
Neurocrine Biosciences, Inc.
Bausch Health Companies Inc.
Vipshop Holdings Limited
Amarin Corporation plc
Pilgrim's Pride Corporation
It's really great to see that even after a strong run, Vipshop Holdings (NYSE:VIPS) shares have been powering on, with...
Intel (INTC) makes a slew of announcements at Supercomputing 2019 event pertaining to its latest GPUs based on Xe architecture, and divulged details on OneAPI software and Aurora exascale system.
As you might know, Skyworks Solutions, Inc. (NASDAQ:SWKS) recently reported its yearly numbers. It was a credible...
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have a high chance of carrying the momentum forward.
The transaction, subject to mandatory closing conditions and shareholder approvals, will help both Softbank (SFTBY) and Line to pool their resources for gaining a strong foothold in the AI domain.
Jazz Pharmaceuticals, Canon, Advanced Energy Industries, Inphi and Skyworks Solutions highlighted as Zacks Bull and Bear of the Day
Hospital stocks gain from a less-than-expected strict price transparency rule and health insurers' optimism on a likely rise in profitability from a low-cost plan.
As you might know, JD.com, Inc. (NASDAQ:JD) recently reported its third-quarter numbers. Sales of CN¥135b surpassed...
It's been a pretty great week for Applied Materials, Inc. (NASDAQ:AMAT) shareholders, with its shares surging 11% to...
(Bloomberg) -- Masayoshi Son, after backing startups around the world, is engineering a complex deal on his home turf to create a national champion that can more effectively compete with global rivals like Google and Amazon.com Inc.Son’s SoftBank Group Corp. plans to combine its Yahoo Japan internet business with Line Corp. in a deal that values the country’s leading messaging service at $11.5 billion. SoftBank and South Korea’s Naver Corp. will take Line private and then fold Line and Yahoo Japan into a new joint venture. The deal requires shareholder approvals and is scheduled to close by October 2020.The two companies said the combination is driven by a sense of crisis that global giants are increasing their grip on the technology industry and countries like Japan risk falling behind. Together, Line and Yahoo Japan, which now operates as Z Holdings Corp., will be able to share engineering resources, access broader sets of data and invest more in areas like artificial intelligence, the chief executive officers said in a Tokyo press conference.“The internet industry often operates on the winner-takes-all principle and the strong only get stronger,” said Line co-CEO Takeshi Idezawa. “Even combined, our market capital, business scale and R&D expenditures are dwarfed by the global tech giants.”At the event, the CEOs gave unusual emphasis to their corporate vulnerabilities and the incumbent risks for Japanese consumers, perhaps in an attempt to preempt government scrutiny of a deal that will combine two of the country’s largest internet companies. The chiefs said they need to join forces to mount a serious challenge to much larger rivals from the U.S. and China.“We want to become an AI tech company that leads the world from Japan,” said Kentaro Kawabe, CEO of Z Holdings. Kawabe wore a bright green tie, Line’s trademark hue, while Idezawa donned one in Yahoo Japan red.Under the proposed transaction, Z Holdings and Naver will buy out Line’s public shareholders in a tender offer at a projected 5,200 yen per share, a 13% premium to Line’s share price before news of the talks. Each company plans to spend 170 billion yen ($1.56 billion) on the bid. Naver already owns 73% of Line, while SoftBank Corp., the domestic telecom arm of Son’s business empire, holds a roughly 44% stake in Z Holdings.The companies have been in talks about a possible alliance since June and settled on the idea of a merger in August, according to the statement. After taking Line private, SoftBank and Naver will undertake a reorganization that will eventually result in a 50-50 ownership of the new company. The combined entity will hold stock in Z Holdings, which will remain public with Yahoo Japan and Line as wholly-owned subsidiaries.SoftBank and Line have increasingly competed in fields such as digital payments, and an alliance may allow them to save money on expenses like subsidies. Both companies have also been investing in artificial intelligence to improve their services. While the announcement didn’t say how the mobile payment rivalry will be resolved, it said the resulting company aims to spend 100 billion yen annually on development of AI-powered products.“Big data is key for the future of both companies,” said Koji Hirai, the head of M&A advisory firm Kachitas Corp. “The merger will enable them to create a massive repository of client data.”Idezawa and Kawabe said there are potential synergies in a number of services areas spanning media content, fintech, advertising, communications and commerce, but didn’t give further details. The combined company will also have about 20,000 employees, a major benefit in an industry where competition for talent intensifies year after year, they said.Steps to the planned merger:Step 1 - Final signing of the deal planned for DecemberStep 2 - Naver and SoftBank to buy out Line’s public shareholders and create a new 50-50 joint ventureStep 3 - SoftBank moves its stake in Z Holdings to the JV, while Z Holdings issues 2.8 billion new shares to the JVStep 4 - Line and Yahoo Japan become fully owned subsidiaries of Z Holdings, which will be owned by the JV. The companies plan to complete the deal by October 2020Silicon Valley giants like Google, Amazon and Facebook Inc. and Chinese startups have taken the lead in both pushing AI development and turning the research into commercial products. That has left most other companies scrambling to attract scarce talent and collect the data necessary to conduct research in fields like deep learning.Line and Yahoo Japan are betting they can leverage local knowledge to stay in the race in their home country and markets where their services are popular, including South Korea, Taiwan, Thailand and Indonesia. Line and Z Holdings shares rose on the deal.Yahoo Japan was once the country’s leading search engine, web portal and major e-commerce player, but has lost ground as users migrated from PCs to smartphones. The company’s online shopping offering has been squeezed by Amazon and Rakuten Inc., while smartphone-native newcomer Mercari Inc. lured customers from its auction service. Yahoo Japan counts some 48 million daily active users across its portfolio of more than 100 mobile phone apps.Line’s origins date back to the turn of the century, when Naver dispatched Shin Jung-ho to Japan to promote its search engine technology. Shin led the company through its first decade in relative obscurity, distributing online games and dabbling in social networking services. In 2010, Line acquired Livedoor Inc., a once high-flying Japanese web portal that had fallen on hard times after its founder was thrown in jail for accounting fraud. It launched Japan’s dominant messaging service in 2011 and went public in 2016.Shin, who shares the CEO title with Takeshi Idezawa at Line, will become the newly created entity’s chief product officer. The post will give him control over the 100 billion yen AI budget and oversight of service development for both Line and Yahoo Japan.Line has 82 million monthly active users in Japan and is also the dominant messenger in Taiwan and Thailand, where it has 21 million and 45 million customers respectively. The company has been expanding into financial services by partnering with Nomura Holdings Inc. and Mizuho Financial Group Inc. It has also been developing a lineup of AI-powered hardware products, including speakers and earphones. Outlays on the new businesses have led to losses in four out of five past quarters.In the Tokyo press conference, the CEOs repeatedly spoke about getting outgunned by GAFA, or Google, Amazon, Facebook and Apple Inc. They said they wouldn’t want see Japan lose out on world-leading services like search and e-commerce, but they want to create a local alternative that can address domestic needs and tastes.“GAFA’s biggest threat is the kind of loyalty they command from their users,” said Kawabe. “We want to give users a domestic AI option. By focusing on Japan’s unique challenges, we can offer services others cannot.”(Updates with the deal strategy from first paragraph.)To contact the reporters on this story: Pavel Alpeyev in Tokyo at email@example.com;Takahiko Hyuga in Tokyo at firstname.lastname@example.orgTo contact the editor responsible for this story: Peter Elstrom at email@example.comFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
(Bloomberg) -- Elizabeth Warren said Friday her Medicare-for-All plan would be implemented over three years, a major concession to the difficulty of fundamentally changing the way Americans get health care. Managed-care and hospital stocks moved higher on the news.A Medium post Warren published Friday mapped out a strategy to enact a mandatory government-run health care system that she estimates would cost $20.5 trillion but others have tagged at more than $30 trillion.Warren said she would inch up to Medicare-for-all, starting with a plan to cover children and poor families. That would happen through a legislative maneuver in her first 100 days in the White House, while not actually eliminating private insurance plans until her third year in office.Health-care companies, which worried about extinction, rallied Friday, leading the S&P 500 Health Index to an all-time high. Among them, some of the nation’s largest insurers such as UnitedHealth Group Inc., Humana Inc., Anthem Inc. and Centene Corp. have climbed more than 5% in Friday’s trading.The advance in health care is a turnaround from the first nine months of the year, when the industry trailed most of its market peers over drug-pricing regulations and Medicare for All proposals.Even if Warren wins the White House and Democrats win control of both the House and Senate, Warren’s timeline is still optimistic, given how Congress operates.She said she would ask Congress to use a quirk in the budget process to allow a simple majority vote -- bypassing the 60-vote Senate threshold -- and “fast-track” a Medicare for All option that would immediately cover children under the age of 18 and families making less than $51,000 a year, and provide an option for expanded Medicare for people over 50.In the first three years, anyone else could buy into Medicare for All at a “modest” cost, Warren said, before it eventually became free.By her third year in office, Warren said, “the American people will have experienced the full benefits of a true Medicare for All option, and they can see for themselves how that experience stacks up against high-priced care that requires them to fight tooth-and-nail against their insurance company.”She added, “I won’t hand Mitch McConnell a veto over my health care agenda,” referring to the current Senate majority leader.After repeated questioning about how she would finance a government-run Medicare for All system that eliminates private insurance, Warren on Nov. 1 rolled out a $20.5 trillion proposal funded by taxing the rich and large corporations.Her gradual implementation “will give people time to adjust, people in the industry will have time to look for other jobs, pension plans will have time to start changing their portfolio and it will give the government time to gear up the bureaucracy,” said Gerald Friedman, professor of economics at the University of Massachusetts at Amherst, who consulted on Bernie Sanders’s 2016 presidential campaign on Medicare for All, the basis of Warren’s plan.The new proposal sets Warren apart from Sanders, who has said he wouldn’t compromise with incremental health-care changes.But Friedman cautioned that a long transition period could leave the private health insurance industry in shambles.“If you know that in three years your company is going to be wiped out, then it could create perverse incentives, staff start exiting and companies may become dysfunctional before the government program is set up,” Friedman said.Warren’s new proposal at least at first ends up looking much like that of her moderate rivals, Joe Biden and Pete Buttigieg: Expanded government-run insurance without mandating it for everyone.Spokesmen for Biden and Buttigieg quickly weighed in.“Senator Warren is now trying to muddy the waters even further,” said deputy campaign manager Kate Bedingfield. “We’re not going to beat Donald Trump next year with double talk on health care.”Buttigieg spokeswoman Lis Smith said, “Senator Warren’s new health care ’plan’ is a transparently political attempt to paper over a very serious policy problem, which is that she wants to force 150 million people off their private insurance -- whether they like it or not.”Even if Democrats control the entire federal government in 2021, their best-case scenario is a narrow Senate majority that would likely leave Warren far short of the votes to pass Medicare for All. And several key Democrats have pledged not to eliminate the legislative filibuster. But the party is more united around the idea of a government-run insurance option.The budget fast-track process, known as reconciliation, has been used by majorities in both parties to avoid a filibuster. Democrats under President Barack Obama used it to pass Obamacare in 2010, while Republicans under President Donald Trump tried to use the procedure to repeal the health-care law in 2017 but came up short.“While Republicans tried to use fast-track budget reconciliation legislation to rip away health insurance from millions of people with just 50 votes in the Senate, I’ll use that tool in reverse – to improve our existing public insurance programs,” Warren wrote.Still, budget reconciliation creates complications as Senate rules require that such legislation be limited to changes involving taxes and spending. Republicans struggled to shoehorn their attempted repeal of Obamacare, which included regulatory reforms, into the process.Warren also vowed to take immediate action to lower drug prices in her first day as president, including insulin, EpiPens and drugs that save people from opioid overdoses. A Warren administration would help companies produce expensive medicines as a price-control measure and use administrative authority to ensure sufficient supply.(Updates with details in first, second, third paragraphs.)\--With assistance from Tatiana Darie.To contact the reporters on this story: Misyrlena Egkolfopoulou in Washington at firstname.lastname@example.org;Sahil Kapur in Washington at email@example.comTo contact the editor responsible for this story: Wendy Benjaminson at firstname.lastname@example.orgFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
We searched for semiconductor stocks utilizing our Zacks Stock Screener that investors might want to consider buying ahead of what could be a strong year for chip companies in 2020...
Henry Kissinger, with decades of experience of dealing with China, gives his assessment on the two countries' relationship.
(Bloomberg) -- Applied Materials shares soared to the highest intraday since early 2018 after the company’s sales forecast topped estimates, prompting a wave of price target increases by analysts.“Applied Materials’ outlook gives the bull narrative more road,” Cowen analyst Krish Sankar wrote, adding that “the path from a ‘nifty fifty’ to a mighty eighty stock got less murky.”Shares of the maker of machinery used in the production of semiconductors had climbed more than 70% this year to nearly $57 before the results were released after markets closed on Thursday. The company’s estimate-beating fourth quarter results followed strong results from peers.“This beat is much better than expected,” Evercore ISI analyst C.J. Muse wrote, pointing to some sell-side previews that called for only an in line forecast.Shares climbed as much as 9.6% to $62.40 on Friday, the highest intraday since March 2018. Here’s what analysts are saying:Cowen, SankarArgues that investors are willing to pay a 15x-16x multiple on peak earnings, creating a path to $80+ per shareAMAT is “seeing early signs of a recovery in 3D NAND flash given 96/128L technology upgrade related spending”Boosts PT to a Street-high $75 from $65, reiterates outperform ratingEvercore ISI, Muse“From here, focus turns to the recovery in 2020”Expects AMAT’s Silicon business to grow by at least 10%, supported by new product introductions as well as sustained new wafer capacity addsRaises PT to $70 from $60 and reiterate outperformRBC Capital, Mitch StevesBelieves the upside to logic/foundry was expected after Lam Research results“We think we’re at the start of a recovery period for semi-cap equipment”Maintains outperform and raise PT to $67 from $63Keybanc, Weston TwiggMargin performance was slightly better than expected and the EPS beat was primarily driven by stronger than expected revenue and $500 million of share buybacks1Q guidance indicates improving demand into 2020, driven by a record backlogExpect demand to improve in 2020 as memory customers restart capacity buildoutsRaise PT to $70 from $54 and maintain overweightTo contact the reporters on this story: Gregory Calderone in New York at email@example.com;Ryan Vlastelica in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Brad Olesen at email@example.com, Will Daley, Jeran WittensteinFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Applied Materials (AMAT) reports strong fiscal fourth-quarter results due to an uptick in demand for semiconductor equipment and solid execution.
(Bloomberg) -- The unanimous panel backing to expand the label for Amarin Corp.’s heart drug Vascepa sparked debate across Wall Street as analysts and investors weighed whether the drug could be sold to as many as 15 million Americans.The divide comes after members of an advisory panel to the U.S. Food and Drug Administration “offered different opinions when it came to specific recommendations for a potential Vascepa label,” according to analysts at Roth Capital Partners. That may leave billions in sales hanging in the balance. But Jefferies’ Michael Yee disagreed, saying the “label debate doesn’t really matter to the thesis” for investors. He believes doctors will use the drug “widely across patients.”Amarin shares climbed as much as 11% Friday after being halted all day Thursday. With the stock briefly nearing $24 a share, it traded about a nickel short of a July peak.Here’s what analysts had to say about the news.Roth Capital Partners, Yasmeen Rahimi“With unanimously favorable response for label expansion, question moves to which patients make it on label, with 10/16 docs voting in favor of both” atherosclerotic cardiovascular disease groups. Roth highlighted that some committee members “were caught up with analysis that showed a 12% relative CV risk reduction” without significant benefit for patients who had not had something like a heart attack or stroke and are at a lower risk.Counted 10 of the 16 panelists “who were receptive to Vascepa label expansion including primary and secondary prevention patients” with the six others wanting the drug’s label to include patients who have had a stroke, or have cardiovascular disease.Says there was “lots of safety talk, but vote indicated AdCom members felt the two signals could be adequately managed through label, thus meaning no patient restrictions.”Maintains buy rating with $31 price target.Jefferies, Michael Yee“Our thesis and valuation are not based on specific ‘details’ of a label as we think docs will use this widely across patients...if stock was down, we think it bounces since label details don’t matter in big picture.”Notes that while Amarin got the positive vote for approval, “investors will debate whether the labeled indication will include a more broad ‘primary prevention’ (high-risk) population which is patients w/o established CV disease but have diabetes and at least one other major” cardiovascular risk factor.Highlights that the “stock has already run-up a lot and we wouldn’t be surprised if it’s volatile on this labeling discussion but we aren’t changing numbers as the populations are huge already.”Maintains buy rating, $30 price target.Cantor Fitzgerald, Louise Chen“There were few-to-no surprises brought up during the meeting, in our view, and we think Vascepa is well on-track now for expected approval by year-end.”Notes that most of the meeting “focused on concerns about the impact of mineral oil, as well as on which patient populations should be included in the label. Although some AdCom members believe mineral oil may have affected results somewhat, they agreed that the REDUCE-IT data are meaningful enough to warrant approval.”Highlighted that panelist discussions on how high patients’ triglycerides, a type of fat in the blood, must be to benefit were “less clear-cut compared to the mineral oil debate.”Maintains overweight rating with a $35 price target.Citi, Joel BeattyAmarin is unlikely to reach a market value above $10 billion over the next several months with its market value at $7.7 billion as of Wednesday’s close.Sees the drug as “likely to be used in high-risk primary prevention patients regardless of” the exact label wording, though there will likely be some debate over the coming weeks regarding the label.“We believe the exact wording of the indication matters relatively little compared to other drugs, because we believe physicians will still use Vascepa in very high risk” primary prevention patients.Maintains buy rating and $23 price target.Stifel, Derek Archila“While the panel was in agreement Vascepa should be approved for secondary prevention patients (our base case), the key question that remains is whether or not Vascepa will receive a broader label inclusive of primary prevention patients, which would be upside to our model.”“We believe approval in secondary prevention alone offers an addressable market that is at least ~10-15 million patients for Vascepa, making us comfortable with our ~$3 billion in peak sales estimate.”Rates shares at buy with a $26 price target.(Updates share movement in third paragraph.)To contact the reporter on this story: Bailey Lipschultz in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Catherine Larkin at email@example.com, Scott Schnipper, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Following the approval, T. Rowe Price (TROW) will be able to offer active strategies without the need to disclose certain information that might be harmful to the interests of fund shareholders.
Rockwell Automation's (ROK) results are likely to be benefit from growth in Life Sciences, Food & beverage markets, acquisitions, focus on productivity amid weak manufacturing, automotive and chemical sectors.